Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.

Status Compound Mechanism of Action Target Indication 
Phase 2       ACT-132577 Endothelin receptor antagonist Resistant hypertension
ACT-541468 Dual orexin receptor antagonist Insomnia
Clazosentan Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus
Phase 1b Lucerastat Glucosylceramide synthase inhibitor Fabry disease
Phase 1       ACT-246475 P2Y12 receptor antagonist Acute coronary syndrome
ACT-774312 CRTH2 receptor antagonist Asthma and allergy disorders
ACT-539313 Selective orexin 1 receptor antagonist Anxiety
ACT-709478 T-type calcium channel blocker Epilepsy

 

"I enjoy working for Idorsia because it has the culture of "let's do it" instead of "it's impossible"."

Application Manager, Corporate IT